MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy.
The increased clinical understanding of neovascularization and its changes during therapy are the basis for therapy-response monitoring with MR mammography of breast cancer treatment. With dynamic MR imaging, objective quantification of neovascularization can be achieved using pharmacokinetic analysis of contrast media enhancement. This technique likely will be of major clinical importance for the noninvasive evaluation of neoadjuvant therapy with a favorable cost-benefit ratio.
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D003287:Contrast Media / Q000493:pharmacokinetics*; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D007089:Image Enhancement / Q000379:methods; D008279:Magnetic Resonance Imaging / Q000191:economics / Q000379:methods; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D012074:Remission Induction
D000970:Antineoplastic Agents; D003287:Contrast Media